In a deal that could top $440 million, Amicus Therapeutics Inc. teamed up with Shire Human Genetic Therapies Inc. on the ex-U.S. development and commercialization of Amicus's three lead pharmacological chaperone compounds for lysosomal storage disorders (LSDs): Amigal, Plicera and AT2220. (BioWorld Today)